statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

Data demonstrates that Company's Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Tribe Public Webinar with Indaptus Therapeutics

 Tribe Public Webinar with Indaptus Therapeutics

 Fully Engaging The Human Immune System To Cure Disease, Featuring CEO, Jeffrey...

Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus...

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics: Q4 Earnings Insights

Indaptus Therapeutics, Inc. (NASDAQ:INDP  Get Free Report) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 17,200...

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 18.6%

Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort Single dose cohort data...

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Gagnants
Le titre Ainos (NASDAQ:AIMD) a mont vendredi de 54,28% 1,62 dollars lors de la session after-market.
Le titre Aadi Bioscience (NASDAQ:AADI) a grimp de 27,60% 2,45 dollars.
Le titre...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 01/03/2024

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...

Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.

Volume	21,270.00
52-Wk High	$4.08
52-Wk Low	$1.56

INDP Indaptus Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals

Sentiment

Message Volume

Community